List view / Grid view
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
Scientists at Virginia Tech’s Fralin Biomedical Research Institute have identified a promising drug target – PRMT5 – that could make treatment-resistant lung, brain and pancreatic cancers more vulnerable to therapy.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
Discover how interactive response technology (IRT) is revolutionising the management of cell and gene therapy (CGT) trials by streamlining complex workflows, ensuring regulatory compliance and enhancing patient outcomes.
Effective financial management is vital for clinical trial success, yet many preclinical and clinical companies face inefficiencies due to outdated systems. Jennifer Kyle, CEO of Condor Software, explains how advanced financial platforms can streamline processes, improve forecasting and ensure better resource allocation throughout drug development.
Singapore researchers have found that cancer drug PRL3-zumab shows strong potential for treating wet age-related macular degeneration and diabetic retinopathy - two leading causes of blindness worldwide.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
In the evolving landscape of cell and gene therapy, early-stage manufacturing remains a major hurdle. In this interview, Maria Knaub at Terumo Blood and Cell Technologies shares how a strategic collaboration with FUJIFILM Biosciences is streamlining T-cell expansion workflows.
Scientists from Fudan University have halted the progression of ALSP, a rare and fatal brain disease, using a pioneering microglia replacement therapy - marking the first effective clinical approach to tackling the disease.
7 July 2025 | By Molecular Devices
Expert insights reveal how 3D cellular models are revolutionising preclinical testing and clinical translation.
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
